Output details
15 - General Engineering
University of Edinburgh (joint submission with Heriot-Watt University)
ApoStream™, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood
This represents the first commercial development of dielectrophoresis, with initial application of identifying the number and type of metastatic cancer cells in a patient’s blood. Current clinical techniques for doing this are limited to extracting cancer cells that express specific antibodies or are much larger than normal circulating blood cells. Dielectrophoresis overcomes these limitations because it is non-invasive, requiring no fluorescent labels or other molecular tags. Prototypes have been delivered by ApoCell Inc (CEO: Darren Davis, email available) to the US National Cancer Institute. Pethig acts as technical consultant for ApoCell Inc and ApoCell Europe GmbH (Leipzig).